About Korea Breast Care

Medical information and hospital coordination for international breast cancer patients.

Korea Breast Care helps international patients prepare medical records, connect with appropriate registered Korean hospitals, and coordinate specialist consultations, treatment schedules and communication before and after travel.

Breast cancer treatment is not a single procedure. Decisions may depend on imaging, pathology, biomarkers, stage, tumour biology, patient preference, systemic therapy, radiotherapy, genetic risk, and whether reconstruction is desired or clinically appropriate.

We prepare and organise the records a hospital needs, help identify the right specialties, guide you to registered institutions and coordinate consultation and travel. Diagnosis, interpretation and treatment planning remain with the clinical team.

Korea Breast Care is operated by DYPHI Inc., a registered international patient facilitator (외국인환자 유치사업자) in Korea and a digital-health and healthcare-coordination company.

See how we coordinate Request a private consultation

Cancer treatment comes before promotion.

Information moves through the whole care pathway

Not every patient follows the same sequence. The order and steps are determined by the treating clinical team.

Our background

DYPHI was founded by internal medicine specialists from Seoul National University and engineers with doctoral training from KAIST.

The company has worked with clinicians, researchers, hospitals, universities, and community health programmes across five continents. Its work has focused on evidence-based healthcare technology, healthy ageing, frailty, sarcopenia, rehabilitation, and functional assessment.

This experience has reinforced a central principle: good healthcare depends not only on access to specialised treatment, but also on the quality, completeness, and continuity of information.

For an international breast cancer patient, this may include:

original imaging rather than screenshots;
pathology reports and, when needed, pathology slides or blocks;
receptor and biomarker results;
clear staging information;
records of previous surgery or systemic treatment;
a coordinated surgical and oncological plan;
understandable information about reconstruction;
English-language treatment records; and
a follow-up plan that continues after returning home.

Why Korea Breast Care was created

Patients considering treatment abroad may encounter polished hospital introductions before they have received a clear explanation of their own diagnosis.

They may be asked to compare surgeons, operations, technology, reconstruction methods, or prices before the underlying medical information has been reviewed properly.

Important questions can be missed:

Has the diagnosis been confirmed by pathology?
Are the imaging and pathology findings consistent?
Are the original DICOM files available?
What is known about stage and tumour biology?
Is treatment needed before surgery?
Is breast-conserving surgery oncologically appropriate?
Will radiotherapy be required?
Is reconstruction optional, immediate, delayed, or not advisable?
Which medical records must be transferred to the next clinical team?
Who will provide oncology follow-up after the patient returns home?

Korea Breast Care was created to organise these questions before treatment or travel decisions are made.

What we do

Explain the treatment pathway

We provide plain-language information about the steps that may be involved in breast cancer care, including:

diagnostic imaging;
pathology review;
staging and biomarkers;
breast-conserving surgery;
mastectomy;
lymph-node evaluation;
systemic therapy;
radiotherapy;
immediate or delayed reconstruction;
postoperative recovery; and
surveillance and long-term follow-up.

The sequence differs between patients and must be determined by the treating clinical team.

Organise published evidence

We summarise research from Korean clinical teams and other relevant sources.

A responsible summary should identify study design, patient population, treatment setting, main outcome, follow-up duration, important limitations, and why a group-level finding cannot determine an individual treatment plan.

RelatedResearch From Korea

Prepare medical records for review

We help patients understand which records may be required for a meaningful specialist review. These may include:

pathology report;
biomarker results;
operative records;
chemotherapy or systemic treatment records;
radiotherapy records;
mammography;
ultrasound;
breast MRI;
CT, PET, or bone imaging where relevant;
original DICOM files;
pathology slides or blocks where requested; and
a concise clinical timeline.

A preliminary review may remain incomplete until original material is examined.

Support communication with appropriate clinical teams

Where appropriate, we may help coordinate communication with a clinical team whose specialty is relevant to the patient’s needs.

This may involve breast surgery, medical oncology, radiation oncology, plastic and reconstructive surgery, radiology, pathology, genetics, rehabilitation, or supportive care. No referral guarantees that a particular treatment or operation will be offered.

RelatedHow a Review Works

Prepare for treatment in Korea

We help patients clarify practical and clinical questions before travel, including:

expected review process;
additional tests that may be required;
likely length of stay;
whether several specialties must be consulted;
timing between surgery and travel;
wound and drain management;
pathology-result timing;
English-language record provision; and
follow-up arrangements in the home country.

Our editorial principles

Cancer treatment comes before promotion

We do not describe a procedure as desirable simply because it is available in Korea. The first question is whether it is oncologically and medically appropriate.

Diagnosis before comparison

Hospital, surgeon, technology, and price comparisons are meaningful only after the diagnosis and treatment requirements are understood.

Evidence requires context

A survival statistic, complication rate, or reconstruction outcome must be interpreted according to the population, stage, treatment era, study design, and follow-up duration.

Newer does not automatically mean better

Robotic, endoscopic, minimally invasive, or other newer surgical techniques should be compared with established alternatives. Technical novelty does not replace oncological safety, appropriate patient selection, or adequate follow-up.

Reconstruction is optional

Reconstruction may be important to some patients and unnecessary or unsuitable for others. We provide information without assuming that every patient wants, needs, or is eligible for reconstruction.

Uncertainty should be visible

When evidence is limited, historical, retrospective, or based on selected patients, that limitation should appear close to the claim.

Records belong in the care pathway

Patients should be able to obtain the records needed for continued treatment, second opinion, rehabilitation, surveillance, or management of complications. International care should not end with discharge from a Korean hospital.

How we consider healthcare providers

We do not rank hospitals only by brand recognition or marketing activity. Relevant considerations may include:

expertise in the patient’s specific diagnosis;
multidisciplinary decision-making;
pathology and radiology review capacity;
breast surgical experience;
reconstructive expertise where relevant;
access to medical and radiation oncology;
management of complex or previously treated cases;
perioperative safety;
rehabilitation and lymphoedema support;
English-language communication;
timely release of medical records and imaging;
postoperative communication; and
coordination with clinicians in the patient’s home country.

Continuity after returning home

Breast cancer care may continue for months or years after surgery.

Depending on the diagnosis and treatment, follow-up may include:

final pathology review;
additional surgery;
chemotherapy;
endocrine therapy;
targeted therapy;
radiotherapy;
wound and drain care;
rehabilitation;
lymphoedema monitoring;
implant or flap follow-up;
surveillance imaging; and
management of treatment-related symptoms.

Before travelling, patients should understand which elements will be provided in Korea and which must continue in their home country.

A written treatment summary and access to relevant records can reduce avoidable gaps in care.

Part of the DYPHI health-information network

DYPHI operates and supports specialised health-information services that share the principles of evidence, transparency, appropriate professional consultation, and continuity of care.

Our continuing commitment

DYPHI began by developing evidence-based healthcare technology with clinical and research teams.

Korea Breast Care applies the same approach to international breast cancer information:

define the clinical question before promoting a service;
distinguish established care from emerging techniques;
place evidence in context;
make limitations visible;
organise records for professional review;
avoid guaranteed access or outcomes; and
plan for continuity beyond the treatment trip.

A responsible international healthcare service should help patients understand not only where treatment may occur, but also why a treatment is being considered, which information supports it, what alternatives exist, and how care will continue afterwards.

Important information

Korea Breast Care and DYPHI are not hospitals, clinics, or medical practices.

The information on this website is provided for general educational and healthcare coordination purposes. It does not constitute medical advice, diagnosis, prescription, or treatment.

We do not independently diagnose breast cancer, interpret pathology for clinical use, prescribe surgery, guarantee eligibility for reconstruction, or guarantee access to a particular clinician or operation.

Final treatment decisions require review of complete medical information by qualified healthcare professionals.

See also our Medical Disclaimer and Editorial Policy.